Immuno-Oncology | Specialty

Rohs Reflects on Therapeutic Approaches in Early- Vs Late-Stage Lung Cancer

December 28th 2020

Nicholas C. Rohs, MD, highlights the influx of clinical trials and the addition of immunotherapy in the adjuvant setting of lung cancer.

Immunotherapy Continues on Positive Trajectory in Lymphoid Malignancies

December 28th 2020

Joshua Brody, MD, discusses established and upcoming immunotherapies in the lymphoid malignancy pipeline.

Nivolumab Plus Temozolomide/Radiotherapy Misses OS End Point in Glioblastoma Multiforme 

December 23rd 2020

December 23, 2020 — Nivolumab in combination with temozolomide and radiation treatment failed to result in a statistically significant improvement in overall survival in patients with newly diagnosed glioblastoma multiforme with MGMT promoter methylation following surgical resection of the tumor.

Dr. Marabelle on Preliminary Findings With SO-C101 in Advanced Solid Tumors

December 21st 2020

Aurélien Marabelle, MD, PhD, discusses preliminary findings from a trial examining SO-C101 in patients with advanced solid tumors.

FDA Grants Priority Review to Frontline Pembrolizumab/Chemo for Locally Advanced Unresectable or Metastatic Esophageal/GEJ Cancer

December 17th 2020

December 17, 2020 - The FDA has granted priority review to a new supplemental biologics license application for pembrolizumab in combination with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment in patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.

Second-Line Motixafortide Plus Pembrolizumab/Chemo Substantially Improves Survival in Stage IV PDAC

December 16th 2020

December 16, 2020 - The combination of motixafortide plus pembrolizumab and chemotherapy was found to result in a substantial improvement in overall survival, progression-free survival, and overall response rate when used as a second-line treatment in patients with stage IV pancreatic ductal adenocarcinoma.

Nivolumab/Ipilimumab Combo Shows Antitumor Activity in Metastatic Uveal Melanoma

December 16th 2020

December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses.

Immunotherapy Agents Drive Treatment Strategies in Frontline Advanced NSCLC

December 16th 2020

Several therapeutic options are available allowing decisions to be made based on histology, PD-L1 expression, and patient preference in regard to their treatment goals.

Pembrolizumab/Lenvatinib Combo Improves Survival, Responses Over Chemo in Advanced Endometrial Cancer

December 16th 2020

December 16, 2020 - Pembrolizumab/lenvatinib has significantly improved survival and responses compared with chemotherapy in patients with advanced endometrial cancer who have received previous systemic treatment.

Dr. Herbst on Biomarkers for Immunotherapy Response in NSCLC

December 16th 2020

Roy S. Herbst, MD, PhD, discusses biomarkers for immunotherapy response that are currently under investigation in non–small cell lung cancer (NSCLC).

x